The drug targets a specific mutation that applies to only 2% of ALS patients. A new drug may slow progression of -- and even reverse -- symptoms of a rare form of amyotrophic lateral sclerosis, or ALS ...

Please provide your email address to receive an email when new articles are posted on . 97 individuals with MS wore an actigraph for 3 to 7 days every 2 to 3 months for up to 24 months. The Vertical ...

Some people with SOD1-ALS experienced improvements in physical function and muscle strength after three years on Qalsody, an ...

Please provide your email address to receive an email when new articles are posted on . The treatment group logged longer times to four disease-progression milestones compared with controls. At 2 ...

When the results of the first-ever platform trial for amyotrophic lateral sclerosis (ALS) were published this February, the headlines might have seemed disappointing: four experimental drugs failed to ...

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a neurodegenerative disease that affects the neurons in the brain and spinal cord. In the United States alone there are ...

Typically, the goal of ALS treatments is to slow the disease or halt progression. But new data from the antisense oligonucleotide (ASO) jacifusen for FUS-ALS show that two patients went beyond the ...

QRL-101, an oral small molecule being developed by QurAlis, was safe and reduced nerve-cell overactivity in ALS patients in ...

New hope could be on the horizon for ALS patients in the form of a "breakthrough" drug, researchers say. Neuvivo, a California biopharmaceutical company that develops therapies for neurodegenerative ...

A new drug may slow progression of — and even reverse — symptoms of a rare form of amyotrophic lateral sclerosis, or ALS, a new study published Monday finds. The drug, tofersen, targets a very ...